EDURANT/rilpivirine — Sales to customers (Note 9)
Johnson & Johnson EDURANT/rilpivirine — Sales to customers (Note 9) increased by 6.8% to $409.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.2%, from $358.00M to $409.00M. Over 4 years (FY 2021 to FY 2025), EDURANT/rilpivirine — Sales to customers (Note 9) shows an upward trend with a 10.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market demand or successful commercialization, while a decrease may signal increased competition, patent expiration, or a shift in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of the specific pharmaceutical product EDURANT (ril...
Peer comparison
Comparable to product-specific revenue line items reported by other pharmaceutical companies, often categorized under specialty or infectious disease therapeutic segments.
jnj_segment_edurant_rilpivirine_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $262.00M | $259.00M | $230.00M | $248.00M | $225.00M | $245.00M | $290.00M | $280.00M | $266.00M | $297.00M | $307.00M | $323.00M | $297.00M | $330.00M | $322.00M | $358.00M | $360.00M | $385.00M | $383.00M | $409.00M |
| QoQ Change | — | -1.1% | -11.2% | +7.8% | -9.3% | +8.9% | +18.4% | -3.4% | -5.0% | +11.7% | +3.4% | +5.2% | -8.0% | +11.1% | -2.4% | +11.2% | +0.6% | +6.9% | -0.5% | +6.8% |
| YoY Change | — | — | — | — | -14.1% | -5.4% | +26.1% | +12.9% | +18.2% | +21.2% | +5.9% | +15.4% | +11.7% | +11.1% | +4.9% | +10.8% | +21.2% | +16.7% | +18.9% | +14.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's edurant/rilpivirine — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported edurant/rilpivirine — sales to customers (note 9) of $409.00M in Q1 2026.
- How has Johnson & Johnson's edurant/rilpivirine — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's edurant/rilpivirine — sales to customers (note 9) increased by 14.2% year-over-year, from $358.00M to $409.00M.
- What is the long-term trend for Johnson & Johnson's edurant/rilpivirine — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's edurant/rilpivirine — sales to customers (note 9) has grown at a 10.6% compound annual growth rate (CAGR), from $994.00M to $1.49B.
- What does edurant/rilpivirine — sales to customers (note 9) mean?
- The total revenue earned from selling the drug EDURANT to customers.